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ARTICLE
Restless legs syndrome in end-stage renal 
disease patients undergoing hemodialysis
Síndrome de Piernas Inquietas en enfermedad renal crónica terminal en hemodiálisis
Sergio Andrés Castillo-Torres1, Héctor Raúl Ibarra-Sifuentes2, Helda Sánchez-Terán1, Concepción Sánchez-
Martínez2, Beatriz Chávez-Luévanos1, Ingrid Estrada-Bellmann1
Restless legs syndrome (RLS) has frequently been 
reported as a complication of end-stage renal disease, partic-
ularly among patients undergoing hemodialysis. In this popu-
lation, it has been associated with decrease in quality of life1, 
and increased prevalence of depression and anxiety2. Also, 
an increased risk for cardiovascular events and mortality 
has been reported in uremic RLS patients3,4 in primary RLS, 
a recent systematic-review and meta-analysis7, demonstrated 
only an increased risk for all-cause mortality and although 
a hyperadrenergic state has been proposed as an explana-
tion5, the precise underlying mechanism is still unknown6. 
In hemodialysis patients, it has been estimated that the prev-
alence of RLS is higher than that reported for the general pop-
ulation, with available evidence yielding a prevalence rang-
ing from 20% to 60%, depending on the criteria used for the 
diagnosis. In Mexico, there is only one study regarding RLS, 
which reported a prevalence of 15.6% among 69,830 healthy 
women8, and studies regarding the prevalence of RLS in 
hemodialysis patients are lacking. Therefore, we designed a 
study to determine the prevalence of RLS in a Mexican popu-
lation of patients undergoing hemodialysis, selecting patients 
who did not meet the criteria for RLS as controls.
METHODS
Ethics
Our study received ethical approval number NF15-001 
from the Institutional Research Ethics Committee on February 
27th, 2015. Due to the nature of the study, only informed (non-
written) assent was required from the subjects.
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ABSTRACT
Restless legs syndrome (RLS) is a frequent complication of hemodialysis that has been associated with poor quality of life and increased risk 
for complications. Nevertheless, few studies regarding this entity exist in resource-limited settings. Objectives: To determine the prevalence 
of RLS among Mexican patients on hemodialysis; and compare these patients with a control group of the same population. Methods: We 
recruited 105 hemodialysis patients. Restless legs syndrome was diagnosed according to the updated criteria set out by the International 
RLS Study Group. We selected patients who did not meet the criteria, as controls. Results: We found an RLS prevalence of 18%. The RLS 
patients had a significantly higher prevalence of iron deficiency anemia and uremic pruritus. None of the patients reported RLS symptoms 
prior to hemodialysis initiation. Conclusions: Restless legs syndrome is common among Mexican patients on hemodialysis. Larger studies 
are required to address the impact of RLS in hemodialysis patients.
Keywords: Restless legs syndrome; renal dialysis; renal insufficiency.
RESUMEN
El síndrome de piernas inquietas (SPI) es una complicación de la hemodiálisis que se ha asociado con menor calidad de vida y riesgo 
aumentado de complicaciones. Sin embargo, existen pocos estudios acerca de esta entidad en escenarios de recursos limitados. Objetivos: 
Determinar la prevalencia de SPI en pacientes mexicanos en hemodiálisis, y comparar las características con un grupo control de la misma 
población. Métodos: Reclutamos 105 pacientes en hemodiálisis. El SPI se diagnosticó de acuerdo con los criterios actualizados del grupo de 
estudio internacional del síndrome de piernas inquietas. Seleccionamos a los pacientes que no cumplieron dichos criterios como controles. 
Resultados: Encontramos una prevalencia de SPI del 18%. Los pacientes con SPI tenían una prevalencia más alta de anemia ferropénica, 
y prurito urémico. Ninguno de los pacientes reportó síntomas de SPI previo a iniciar la hemodiálisis. Conclusiones: El SPI es frecuente en 
pacientes mexicanos en hemodiálisis; se requieren estudios más grandes para evaluar el impacto del síndrome en ésta población.
Palabras-clave: Síndrome de piernas inquietas; diálisis renal; insuficiencia renal.
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Study population
We evaluated 105 patients from the chronic hemodialysis 
program at our hospital, through a physician-directed inter-
view. The presence of RLS was defined by fulfillment of the 
essential diagnostic criteria set out by the International RLS 
Group9. Clinical characteristics of patients were obtained by 
direct interview, and paraclinical parameters were retrieved 
through medical record review. The control group comprised 
86 patients who did not meet the criteria for RLS, recruited 
while searching for RLS in our hemodialysis program.
Statistical analysis
We performed statistical analysis of categorical variables 
using percentage, and for numerical variables, mean and 
standard deviation, or median and range were used where 
appropriate. To compare variables between patients and con-
trols, we used the Chi square test for categorical variables; 
and for numerical variables, the t test and Mann-Whitney U 
test were used according to the distribution of the variable, 
as evaluated by the Kolmogorov-Smirnov test. Binary logis-
tic regression was performed to test the association between 
RLS (present/absent as dependent variable) and the follow-
ing variables at evaluation as regressors: iron-deficiency ane-
mia (yes/no), length of time undergoing hemodialysis, pruri-
tus (yes/no), and hemoglobin. 
RESULTS 
We found 19 patients with RLS (an estimated 18% preva-
lence). None of them reported symptoms or diagnosis of RLS 
prior to the development of end-stage renal disease or initia-
tion of hemodialysis therapy.
Age, sex, and comorbidities were not statistically dif-
ferent between patients with RLS and controls. Among 
comorbidities, only iron-deficiency anemia was statistically 
different between RLS patients and controls (63.2% vs. 37.2%, 
p= 0.038).  Clinical characteristics are detailed in Table 1.
When compared with controls, RLS had non-significant 
lower hemoglobin (7.91 g/dL vs. 8.79 g/dL, p = 0.064) and 
hematocrit (24.8% vs. 27.7%, p = 0.055); and other red blood 
cell indices, such as mean corpuscular volume and mean 
hemoglobin concentration, were not statistically different 
(Table 2).
The presence of uremic pruritus was significantly higher 
in patients with RLS than controls (42.1% vs. 20.5%, p = 0.039). 
The course of renal disease, renal replacement therapy, and 
renal function surrogates (blood urea nitrogen, serum cre-
atinine, and estimated glomerular filtration rate) were not 
different between groups. Serum electrolyte levels were 
within normal ranges, and did not differ between groups. 
Paraclinical characteristics are detailed in Table 2.
Binary logistic regression analysis showed a non-signifi-
cant trend for iron-deficiency anemia, uremic pruritus and 
hemoglobin to predict RLS (Table 3), while the length of time 
undergoing hemodialysis was not significant.
DISCUSSION
Our study found an 18% prevalence of RLS in a Mexican 
hemodialysis population; this prevalence is lower than that 
reported in previous studies, which ranged from 20% to 60%, 
but similar to the only report from our country: 15.6% in a 
healthy population of 69,830 women8. We must emphasize 
that this previous Mexican study, although very valuable 
for being the first to determine the prevalence of RLS, has 
the limitation that the authors did not use the International 
RLS Study Group criteria, and patients were asked to answer 
questions regarding symptoms of RLS, which makes it diffi-
cult to ascertain this as the prevalence in a healthy Mexican 
population. As for the prevalence reported around the world, 
Table 1. Clinical characteristics of RLS patients and controls.
Variable RLS Controls p-value*
Number of participants 19 86 na
Age (years). 45.5 ± 17.1 50.2 ± 16.0 0.253a
Female sex – no. (%) 11 (57.9%) 47 (54.7%) 0.797b
Hypertension – no. (%) 18 (97.4%) 77 (89.5%) 0.485 a
Diabetes mellitus – no. (%) 11 (57.9%) 48 (55.8%) 0.869 a
Iron-deficiency anemia – no. (%) 12 (63.2%) 32 (37.2%) 0.038 a
Peripheral neuropathy – no. (%) 2 (10.5%) 6 (7.0%) 0.598 a
Cerebrovascular disease – no. (%) 2 (10.5%) 4 (4.7%) 0.318 a
Duration of end-stage renal disease (years) 2.5 (0.04–9.0) 2.0 (0.2 – 25.0) 0.980c
Duration of undergoing hemodialysis (years) 2.0 (0.04–7.0) 1.65 (0.04 – 13.0) 0.851 c
Number of hemodialysis sessions per week – no. (%) 2.0 (1.0–3.0) 2.0 (1.0 – 4.0) 0.541 c
Total number of hemodialysis sessions – no. 129 (5–397) 93 (7 – 483) 0.573 c
Type of access: intravenous catheter. – no. (%) 19 (100%) 76 (91.6%) 0.167 a
Uremic pruritus – no. (%) 8 (42.1%) 17 (20.5%) 0.039 a
RLS: restless legs syndrome; *significant difference at .05 level; ap-value: calculated using the Chi square test; bp-value: calculated using t test; cp-value: 
calculated using the Mann-Whitney U test.
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results have been heterogeneous, due to differences in crite-
ria used for the diagnosis of RLS.
Among differences between RLS patients and controls, 
we found a significantly higher prevalence of self-reported 
iron-deficiency anemia. Although iron deficiency has been 
implicated in the pathogenesis of idiopathic RLS, available 
evidence (summarized by a recent review10) suggests that 
disturbances in the brain’s iron metabolism correlate with 
RLS11, while serum iron parameters do not12.  
We found a significantly higher prevalence of uremic pru-
ritus in patients with RLS. We did not find any previous stud-
ies that associated RLS with uremic pruritus, and the prev-
alence in our RLS patients was similar to that reported by 
previous studies in non-RLS patients13; both entities have 
been unsuccessfully proposed as surrogates for inadequate 
dialysis14. Surrogates of renal function, such as serum creat-
inine, blood urea nitrogen or glomerular filtration rate, did 
not differ between the RLS patients and controls. While this 
could suggest that RLS does not develop as a result of inad-
equate dialysis, many substances that accumulate in end-
stage renal disease are not routinely measured and the per-
fect marker for dialysis adequacy has not been found.
Our study is the first to evaluate RLS in a Latino popula-
tion of patients undergoing hemodialysis using the updated 
Table 2.  Paraclinical characteristics of RLS patients and controls.
Variable RLS Controls p-value*
Number of participants 19 86 na
Hemoglobin (g/dL) 7.91 ± 1.38 8.79 ± 1.89 0.064a
Hematocrit (%) 24.8 ± 4.3 27.7 ± 5.9 0.055a
Mean corpuscular volume (fL) 90.3 ± 7.4 91.3 ± 6.0 0.537a
Mean hemoglobin concentration (pg) 28.9 ± 2.8 28.9 ± 2.1 0.999a
Platelet count (cell/mm3) 189,837 ± 68,866 193,764 ± 75,257 0.819b
Mean platelet volume (fL) 7.12 ± 1.38 6.80 ± 1.40 0.341b
Blood urea nitrogen (mg/dL) 53.6 ± 27.3 61.5 ± 26.8 0.246a
Serum creatinine (mg/dL) 9.7 ± 3.6 9.0 ± 3.7 0.462a
eGFR-MDRD-4 (mL/min/1.73m2) 7.3 ± 3.2 8.3 ± 6.8 0.821b
Sodium (mmol/L) 137.1 ± 2.9 137.3 ± 4.0 0.848a
Potassium (mmol/L) 5.0 ± 0.9 5.3 ± 1.0 0.398b
Chloride (mmol/L) 101.9 ± 4.8 101.7 ± 4.6 0.886a
Magnesium (mg/dL) 2.7 ± 0.4 2.8 ± 0.6 0.288b
Phosphorus (mg/dL) 5.1 ± 1.5 5.1 ± 1.7 0.987a
Calcium (mg/dL) 8.2 ± 0.9 8.4 ± 1.1 0.699b
*Significant difference at .05 level; RLS: restless legs syndrome; eGFR-MDRD4: estimated glomerular filtration rate calculated with MDRD 4 element formula; 
ap-value: calculated using t test; bp-value: calculated using the Mann-Whitney U test.
Table 3. Predictors of restless legs syndrome by binary logistic regression analysis.
Variable Beta SE p-value OR 95%CI
Iron deficiency anemia -0.950 0.545 0.082 0.4 (0.1–1.1)
Duration of undergoing hemodialysis (years) -0.044 0.145 0.759 1.0 (0.7–1.3)
Uremic pruritus  -0.915 0.555 0.099 0.4 (0.1–1.2)
Hemoglobin -0.304 0.183 0.096 0.7 (0.5–1.1)
Dependent variable: restless legs syndrome (present/absent); Predictors: iron-deficiency anemia (yes/no); duration undergoing hemodialysis; pruritus (yes/no); 
hemoglobin level.
International RLS Study Group criteria, which have not been 
used uniformly for diagnosis across available studies.
Our main limitation is the small study sample, which 
makes it difficult to establish solid differences between 
patients and controls. We acknowledge that our study lacks 
invasive or detailed neurophysiological and biochemical 
measurements that help characterize RLS, such as polysom-
nographic studies or serum iron status, or dialysis adequacy 
parameters, such as urea reduction rate. Another important 
limitation is that we could not measure parathyroid hor-
mone levels. In hemodialysis patients without RLS, evidence 
linking pruritus and parathyroid hormone has been conflict-
ing15,16, while in uremic RLS, elevated parathyroid hormone 
levels have been associated with poor sleep quality17, and 
in patients with severe hyperparathyroidism, surgical treat-
ment (parathyroidectomy) resulted in an improvement of 
RLS symptoms18. Despite limitations, our findings are useful 
because they represent the patients encountered in an ordi-
nary practice in a resource-limited setting, such as Mexico. 
Larger epidemiological studies are required to further assess 
and define the characteristics of RLS in hemodialysis patients 
in high risk populations such as Latinos, with a special focus 
on paraclinical correlates such as parathyroid hormone, in 
order to elucidate the association with RLS.
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In conclusion, RLS is a common complication in end-
stage renal disease patients undergoing hemodialysis, and 
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larger studies are required to fully understand the causes and 
consequences of RLS in hemodialysis patients.
